Challenges in Psychedelic Medicine - Part 2: Ethical and Scientific Hurdles

Before starting I recommend you check out: PART ONE

In recent years there has been a resurgence of interest in psychedelic substances as potential treatments for mental health disorders. This has of course created much excitement and controversy. While early research suggests that psychedelics such as MDMA, psilocybin, and LSD could prove transformative for this with conditions like depression, anxiety, and post-traumatic stress disorder (PTSD). Recent developments have highlighted significant ethical and scientific challenges within the field. In my previous article I discussed the case of Lykos Therapeutics and the FDA's rejection of their MDMA-assisted psychotherapy. This serves as a focal point for examining these issues, which we will build upon here. I recommend you read article one prior to continuing with this piece.

As we have discussed, wellness culture can foster an obsession with healing which can become counterproductive. The fervour surrounding psychedelic research may inadvertently overlook critical flaws in methodology and lead to counterproductive results in just the same way. An excessive focus on achieving breakthroughs can cause not only confirmation bias, but also active avoidance of any perceived negative results - paralleling the pitfalls sometimes seen in personal wellness pursuits. This hinders genuine progress and, in some cases, exacerbates the very problems they aim to solve.

One of the most potentially concerning aspects of psychedelic research is the overlap between researchers' personal experiences with these substances and their professional roles. As with Timothy Leary and others during the first psychedelic renaissance of the 60s and 70s, the culture within the community often encourages therapists and researchers to undergo psychedelic experiences themselves. This is purportedly as a means to enhance their empathy and increase their understanding toward patients, and of the experiences themselves. While this might seem beneficial on the surface, it can introduce significant ethical dilemmas.

For example, some researchers openly advocate for the therapeutic potential of psychedelics based on their seemingly transformative personal experiences. This removes all impartiality from any study they are attempting to carry out. The intersection of personal belief and professional practice can lead to unconscious biases, affecting study design, data interpretation, and the handling of adverse events.

The risk here mirrors the perfectionism seen in wellness culture, where the relentless pursuit of some perceived ideal state of being can blind individuals to potential flaws and ethical oversights.

The drive to present psychedelics as flawless solutions can foster a perfectionist mindset among researchers and clinicians. This perfectionism can manifest in several ways:

1. Selective Reporting: There may be a tendency to highlight positive outcomes while downplaying or ignoring negative results and adverse effects. This skews the scientific literature and creates unrealistic expectations.
2. Resistance to Criticism: Researchers might dismiss valid critiques of their methodologies or findings, viewing them as threats to their mission rather than opportunities for growth.
3. Overextension: In an effort to explore every possible application of psychedelics, researchers may stretch their resources thin, leading to poorly designed studies and inadequate oversight.

The allegations of unethical conduct within Lykos's clinical trials, including inappropriate behaviour by an unlicensed therapist, highlight vulnerabilities that arise when boundaries are not strictly enforced. Psychedelic therapy often involves patients entering altered states of consciousness. This consequently increases their suggestibility and vulnerability. This means that the maintenance of clear professional boundaries between patients and researchers is paramount. Any issues pertaining to the misuse of or manipulation of this heightened suggestibility not only harm patients but also undermine public trust in psychedelic research.

In just the same way as the wellness industry psychedelic research faces criticism for biassed experimentation, unqualified practitioners and exploitation. The importance of facing these ethical lapses head-on and publically cannot be understated. Without stringent ethical standards, the promise of these therapies can be overshadowed by incidents that cause more harm than good.

Furthermore, the normalisation of certain practices within the community, like the use of "nurturing touch" or the encouragement of close personal bonds between therapist and patient—can blur professional lines. While these practices may be well-intentioned, they increase the risk of boundary violations and must be carefully regulated.

A common pitfall in both wellness culture and psychedelic research is excessive self-focus. In wellness pursuits, this can lead to isolation and neglect of social relationships, which are crucial for well-being. Similarly, in psychedelic research, an overemphasis on individual projects or theories can hinder collaboration and the sharing of knowledge.

This self-centred approach may result in:

• Duplication of Effort: Researchers working in silos might unknowingly replicate studies, wasting valuable resources.
• Competitive Environment: A focus on personal achievement over collective progress can foster competition rather than collaboration, slowing overall advancements.
• Lack of Peer Review: Avoiding external input can lead to unchecked biases and methodological flaws.

Psychedelic research faces unique methodological hurdles that complicate the interpretation of results:

1. Blinding Difficulties: Due to the noticeable effects of psychedelics, maintaining a double-blind study is challenging. Participants and researchers often can tell who has received the active drug versus a placebo, introducing bias.
2. Placebo Effect and Suggestibility: Psychedelics can enhance suggestibility, making participants more receptive to therapeutic suggestions. While this can be beneficial if treated ethically, it is highly manipulatable. This raises questions about whether improvements are due to the drug itself, or the therapeutic context in which it was administered.
3. Small Sample Sizes: Regulatory restrictions and the intensive nature of psychedelic therapy sessions often limit sample sizes, affecting the statistical power of studies.
4. Short-Term Follow-Up: Many studies focus on immediate outcomes without assessing the long-term sustainability of therapeutic effects.

To mitigate blinding difficulties, researchers have experimented with using active placebos—substances that produce mild psychoactive effects without the therapeutic benefits of the psychedelic being studied. This approach aims to make it harder for participants and researchers to distinguish between the treatment and control groups. However, even active placebos may not fully replicate the profound experiences induced by psychedelics, so alternative strategies are needed.

Some researchers advocate for open-label studies that acknowledge the impossibility of perfect blinding but focus on other methodological strengths, such as robust control groups and objective outcome measures. While this doesn't eliminate bias, it allows for transparency and the acknowledgment of limitations.

An underlying theme in both wellness culture and psychedelic advocacy is scepticism toward conventional medical treatments. While questioning established practices can drive innovation, it becomes problematic when it leads to wholesale rejection without sufficient evidence.

In the context of psychedelic research:

• Neglecting Established Therapies: Focusing exclusively on psychedelics to the detriment of other potential substances may ignore existing, evidence-based treatments. Sometimes these treatments are proven and effective.
• Alternative vs. Complementary: Psychedelic therapies are sometimes presented as alternatives rather than complements to traditional treatments. This can limit integrated care approaches and lessen their effectiveness.
• Risk of Misinformation: Overstating the benefits and downplaying the risks of psychedelics can mislead patients and the public.

The concept of spiritual bypassing - using spiritual practices to avoid confronting unresolved emotional issues - is prevalent in wellness circles. A similar phenomenon can occur in psychedelic research and therapy.

Researchers and therapists might:

• Overlook Underlying Issues: Focusing on inducing profound experiences without addressing the root causes of mental health conditions.
• Neglect Integration: Failing to provide sufficient support for patients following the experience to fully integrate their psychedelic experiences into their daily lives. This will limit any long-term benefits.
• Promote Escapism: Emphasising the transcendental or spiritual aspects of psychedelics could encourage avoidance of real-world problems.

Addressing ethical challenges requires the establishment of robust training programs and professional standards for those involved in psychedelic research and therapy.

Key components include:

• Standardised Training: Developing rules and guides of the technical aspects of administering psychedelics. This must include ethical considerations also, cultural competence, and patient safety.
• Certification and Accreditation: Implementing certification will ensure that practitioners not only themselves adhere to the established standards, but are also expected to do so. This is no different to other medical and therapeutic professions.
• Ongoing Education: Encouraging continuous learning to update knowledge of the latest research, developments in ethical guidelines, and best practices for experimentation and application.

Psychedelics have a rich history in indigenous cultures across the globe. A variety of substances are used in ceremonial and healing practices. Modern research must respect and learn from these traditions.

• Cultural Appropriation vs. Appreciation: Avoiding the exploitation of indigenous knowledge and practices by engaging in respectful collaboration and acknowledgment.
• Diversity in Research: Ensuring that study participants represent diverse backgrounds to understand how psychedelics may affect different populations.
• Global Perspectives: Learning from international research and regulatory approaches to increase collaboration and improve the field as a whole.

Constructive engagement with regulatory agencies like the FDA is essential for advancing psychedelic research responsibly. This involves:

• Transparency: Openly sharing methodologies, data, and adverse events to build trust and credibility.
• Compliance: Adhering strictly to regulatory requirements and guidelines to ensure patient safety and data integrity.
• Advocacy: Working collaboratively to address regulatory barriers that hinder research while respecting the need for oversight.

Healing is multifaceted, involving biological, psychological, social, and spiritual dimensions. Psychedelic research must adopt a holistic approach that considers:

• Interdisciplinary Collaboration: Partnering with experts in psychology, psychiatry, neuroscience, sociology, and anthropology to compare and contrast research perspectives.
• Community Engagement: Involving patients, advocacy groups, and diverse communities in the research process to ensure relevance and inclusivity.
• Addressing Social Determinants of Health: Recognising that factors like socioeconomic status, discrimination, and trauma impact mental health and must be addressed alongside individual treatment.

Advancements in technology offer new opportunities to enhance psychedelic research and therapy:

• Digital Monitoring: Utilising wearable devices and mobile applications to track physiological and psychological changes during and after treatment.
• Virtual Reality (VR): Integrating VR into therapy sessions to create controlled environments that can enhance or simulate psychedelic experiences without the use of substances.
• Data Analytics: Employing advanced analytics to interpret complex data sets, improving understanding of how psychedelics affect the brain and behaviour.

Misinformation and stigma surrounding psychedelics persist, often fueled by their association with illegal drug use and past cultural movements. Educating the public is crucial for:

• Reducing Stigma: Promoting understanding of psychedelics as potential therapeutic tools rather than solely recreational substances.
• Informed Decision-Making: Providing accurate information to help individuals make informed choices about participating in research or seeking therapy.
• Policy Support: Building public support for policy changes that facilitate responsible research and access to treatments.

The ethical and scientific challenges surrounding psychedelic research are significant. However, they are far from insurmountable. Taking into account the already widely recognised parallels with the pitfalls of wellness culture. Issues such as perfectionism, excessive self-focus, and avoidance we can take fairly simple, proactive steps to address these issues.

Increasing the emphasis on rigorous scientific methods, ethical integrity, and holistic approaches will strengthen the field and enhance its credibility. The pressures of funding cannot be allowed to compromise the integrity of experimentation. Collaboration, transparency, and respect for a variety of perspectives are key.

Healing is a journey that takes concerted, prolonged effort. In both personal wellness and scientific exploration, shortcuts will inevitably lead to setbacks. By committing to ethical excellence and embracing a comprehensive understanding of well-being, we can unlock the transformative potential of psychedelics responsibly and compassionately.

Ultimately, the goal is not just to alleviate symptoms but to, if not create, then actively contribute to a healthier, more connected society. Psychedelic research, when conducted carefully, holds the promise of offering potentially life-changing treatments which honour both individual needs and collective well-being.